Category: Company Focus

Long Term Aim for Biotech Companies

Since the economy went sideways in 2008 the stock market seems to have a tarnished image. One area of investment that is helping investors feel good about what they are doing is Biotech. The three sectors of the biotech industry that have done well and will continue to do well moving farther into the 21st century are 3D Printing, Nanotechnology, and Pharmaceuticals. Many experts predict this market will grow to several hundred billion over the decade. The great thing about these companies is that while they create a lot of value as an investment they also create a lot...

Read More

Codexis (NASDAQ:CDXS)

If you blinked over the last week and weren’t monitoring the latest stock movements, you might have missed Codexis, Inc (CDXS). While most industry analysts were commenting on the drop off in early year training, there were several movers and shakers, including Codex. With an eight percent rise on Friday, the company is starting to push in a strong performance over the last week and a half. As many stocks, it dropped off right at the end of the year as investors attempted to prepare for the 2016 tax season. Since the late 2015/early 2016 sell off period though,...

Read More

3 Scorned Biotech Stocks Poised For a Rebound

August hit the biotech industry hard, but all hope is not lost; following are several biotech companies that look as though they’ll rebound. The trends to look for are as follows: acquisition of additional pharmaceutical/biotech agencies, development of treatment options which pass clinical trials, and development of treatments for conditions which previously had no treatment. Akebia and Valadustat Akebia Therapeutics (AKBA) has seen some very heartening results during the clinical trials for valadustat. For patients forced into renal dialysis, valadustat is a drug which aids in proper blood levels, ensuring hemoglobin is at the correct saturation. As a result,...

Read More

Analysts Set $6.00 Price Target for Sinovac Biotech Ltd. (NASDAQ:SVA)

Biotech organizations are a more and more steady investment today, and Sinovac is a biopharmaceutical company whose focus on research and development is strengthened by further manufacture and commercialization of various vaccinations. Hepatitis A and B are among the vaccinations offered by Sinovac, but one of the most well-known is going to be seasonal influenza. Investing in organizations that purvey flu shots is a fairly steady kind of investment, provided the organization is like Sinovac and is showing strong numerical increase over time. Sinovac also has inoculations against mumps, animal rabies, H5N1, pandemic influenza, the H1N1 virus, and various...

Read More

The Never Ending War on Cancer

There is a certain insidious truth to the title of this piece. The war on cancer is a never-ending one, because cancer is multifaceted, and there isn’t any one specific type of cure. Furthermore, internationally modernity encourages behavior that systematically facilitates the development of cancerous ailments. From alcoholism to smoking, from untested genetically modified foodstuffs to aspartame and its cancer/Alzheimer’s linkage, and even negative health developments which stem from technology use, cancer isn’t just a genetic predisposition. Radiation, medication, and a marked lack of exercise also characterize cancerous populations. As a result, biotech companies facilitating demonstrably effective cancer treatments...

Read More